Troriluzole

also known as BHV-4157 · BHV-4157 HYDROCHLORIDE · BHV-4157a · FC-4157 · trigriluzole · TRORILUZOLE HYDROCHLORIDE

Developed for: obsessive-compulsive disorder · spinocerebellar ataxia type 1 · spinocerebellar ataxia type 2 · spinocerebellar ataxia type 6 · glioblastoma · Machado-Joseph disease · metastatic melanoma · spinocerebellar ataxia 7
+15 more
· spinocerebellar ataxia type 10 · spinocerebellar ataxia type 8 · Alzheimer disease · brain neoplasm · cerebellar ataxia · classic Hodgkin lymphoma · cutaneous melanoma · generalized anxiety disorder · head and neck squamous cell carcinoma · Machado-Joseph disease type 3 · metastatic malignant neoplasm · multiple system atrophy, cerebellar type · non-small cell lung carcinoma · renal cell adenocarcinoma · urinary bladder carcinoma
Investigated by: Biohaven Pharmaceuticals, Inc. · Alzheimer's Disease Cooperative Study (ADCS) · AstraZeneca · Bayer · Dana-Farber Cancer Institute · Global Coalition for Adaptive Research
+10 more
· Kazia Therapeutics Limited · Kintara Therapeutics, Inc. · Knoa Pharma LLC · National Cancer Institute (NCI) · National Institutes of Health (NIH) · Polaris Group · Rutgers, The State University of New Jersey · Ugonma Chukwueke · University of California, Los Angeles · Vigeo Therapeutics, Inc.

Trials 13 · a red edge is where a trial was stopped

today NCT06552260 · Ph 0 NCT04899921 · Ph 2 NCT04708834 · Ph 3 NCT04693351 · Ph 3 NCT03970447 · Ph 2/3 NCT03701399 · Ph 3 NCT03829241 · Ph 3 NCT03605667 · Ph 2 NCT03299166 · Ph 2/3 NCT03408080 · Ph 3 NCT03229278 · Ph 1 NCT02960893 · Ph 2/3

201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT06552260	Feb 2025 → Aug 2026 overdue	brain neoplasm, glioblastoma	Ugonma Chukwueke	Recruiting	No outcome recorded
Phase 11 trial
Phase 1	NCT03229278	Oct 2017 → Oct 2022	classic Hodgkin lymphoma, cutaneous melanoma, head and neck squamous cell carcinoma, metastatic malignant neoplasm +4	Rutgers, The State University of New Jersey	Completed	No outcome recorded
Phase 22 trials
Phase 2	NCT04899921	Jun 2021 → May 2023	metastatic melanoma	Dana-Farber Cancer Institute	Terminated	No outcome recorded
Phase 2	NCT03605667	Jul 2018 → Dec 2020	Alzheimer disease	Biohaven Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2/33 trials
Phase 2/3	NCT03970447	Jul 2019 → Jun 2028 expected	glioblastoma	Global Coalition for Adaptive Research	Recruiting	No outcome recorded
Phase 2/3	NCT03299166	Dec 2017 → Jun 2020	obsessive-compulsive disorder	Biohaven Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2/3	NCT02960893	Dec 2016 → Aug 2017	Machado-Joseph disease type 3, spinocerebellar ataxia 7, spinocerebellar ataxia type 1, spinocerebellar ataxia type 10 +3	Biohaven Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 35 trials
Phase 3	NCT04708834	Mar 2021 → Feb 2026	obsessive-compulsive disorder	Biohaven Pharmaceuticals, Inc.	Terminated	No outcome recorded
Phase 3	NCT04693351	Jan 2021 → Apr 2025	obsessive-compulsive disorder	Biohaven Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 3	NCT03701399	Mar 2019 → Feb 2022 overdue	Machado-Joseph disease, spinocerebellar ataxia 7, spinocerebellar ataxia type 1, spinocerebellar ataxia type 10 +3	Biohaven Pharmaceuticals, Inc.	Active not recruiting	No outcome recorded
Phase 3	NCT03829241	Feb 2019 → Jan 2020	generalized anxiety disorder	Biohaven Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 3	NCT03408080	Dec 2017 → Dec 2024 overdue	Machado-Joseph disease, multiple system atrophy, cerebellar type, spinocerebellar ataxia type 1, spinocerebellar ataxia type 2 +1	University of California, Los Angeles	Active not recruiting	No outcome recorded
Phase not stated1 trial
—	NCT06034886	—	cerebellar ataxia	Biohaven Pharmaceuticals, Inc.	Available	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT04641143 Comparator	Dec 2020 → Oct 2025	obsessive-compulsive disorder	Biohaven Pharmaceuticals, Inc.	Completed	No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 16 sources stand behind the page.

Field	Value	Cited text
Known as	troriluzole	“the riluzole prodrug troriluzole (BHV-4157, trigriluzole) and the PD-1 antibody nivolumab” PMID 35780243 ↗ Jul 2022 12 NCT03970447 ↗ NCT03605667 ↗ NCT02960893 ↗ NCT03701399 ↗ NCT04708834 ↗ NCT06034886 ↗ NCT03299166 ↗ NCT04899921 ↗ NCT06552260 ↗ NCT03829241 ↗ NCT04693351 ↗ NCT04641143 ↗
Known as	BHV-4157	“The primary purpose of this study was to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in participants...” NCT02960893 ↗ 4 “Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder” NCT03299166 ↗ “Trigriluzole (FC-4157/BHV-4157)” NCT03229278 ↗ “Troriluzole (BHV-4157)” NCT04708834 ↗ NCT03408080 ↗
Known as	BHV-4157 HYDROCHLORIDE	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297586 ↗
Known as	BHV-4157a	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297586 ↗
Known as	FC-4157	“Trigriluzole (FC-4157/BHV-4157)” NCT03229278 ↗
Known as	trigriluzole	“Given trigriluzole PO” NCT03229278 ↗
Known as	TRORILUZOLE HYDROCHLORIDE	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297586 ↗
Action	Inhibit	“Trigriluzole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT03229278 ↗
Modality	Peptide	“Tripeptide prodrug of Riluzole” NCT06552260 ↗
Route	Oral	“Troriluzole 140 mg capsules orally once daily (QD) for 8 weeks.” NCT02960893 ↗